SEC Form 4 · accession 0001012975-17-000923
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derace L Schaffer
Director
Period of report
Dec 6, 2017
Accepted (ET)
Dec 8, 2017 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F1 | Dec 6, 2017 | P | 16,106 | $1.8003 | A | 337,274 | D | |
| Common Stock, par value $0.0001F2 | Dec 7, 2017 | P | 7,639 | $1.7421 | A | 344,913 | D | |
| Common Stock, par value $0.0001 | holding | — | — | — | 12,393 | I | IRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.76 to $1.86 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
- F2The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.70 to $1.79 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.